Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

Stephen D Wiviott; Marcus D Flather; Michelle L O'Donoghue; Shinya Goto; Desmond J Fitzgerald; Fernando Cura; Philip Aylward; Victor Guetta; Dariusz Dudek; Charles F Contant; Dominick J Angiolillo; Deepak L Bhatt; LANCELOT-CAD Investigators

doi:10.1161/CIRCULATIONAHA.110.001404

Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

Stephen D Wiviott, Marcus D Flather, Michelle L O'Donoghue, Shinya Goto, Desmond J Fitzgerald, Fernando Cura, Philip Aylward, Victor Guetta, Dariusz Dudek, Charles F Contant, Dominick J Angiolillo, Deepak L Bhatt, LANCELOT-CAD Investigators

Research output: Contribution to journal › Article › peer-review

Abstract

Thrombin is a key mediator of platelet activation. Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes with thrombin-mediated platelet effects. The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD.

Original language	English
Pages (from-to)	1854-63
Number of pages	10
Journal	Circulation
Volume	123
Issue number	17
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.110.001404
Publication status	Published - 3 May 2011

Keywords

Aged
Biological Markers
Blood Platelets
Coronary Artery Disease
Dose-Response Relationship, Drug
Female
Hemorrhage
Humans
Imines
Male
Middle Aged
Platelet Activation
Platelet Aggregation Inhibitors
Pyridines
Receptors, Thrombin

Access to Document

10.1161/CIRCULATIONAHA.110.001404

Cite this

Wiviott, S. D., Flather, M. D., O'Donoghue, M. L., Goto, S., Fitzgerald, D. J., Cura, F., Aylward, P., Guetta, V., Dudek, D., Contant, C. F., Angiolillo, D. J., Bhatt, D. L., & LANCELOT-CAD Investigators (2011). Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial. Circulation, 123(17), 1854-63. https://doi.org/10.1161/CIRCULATIONAHA.110.001404

@article{398fec943fe74584bd305c8ce379c1a2,

title = "Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial",

abstract = "Thrombin is a key mediator of platelet activation. Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes with thrombin-mediated platelet effects. The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD.",

keywords = "Aged, Biological Markers, Blood Platelets, Coronary Artery Disease, Dose-Response Relationship, Drug, Female, Hemorrhage, Humans, Imines, Male, Middle Aged, Platelet Activation, Platelet Aggregation Inhibitors, Pyridines, Receptors, Thrombin",

author = "Wiviott, {Stephen D} and Flather, {Marcus D} and O'Donoghue, {Michelle L} and Shinya Goto and Fitzgerald, {Desmond J} and Fernando Cura and Philip Aylward and Victor Guetta and Dariusz Dudek and Contant, {Charles F} and Angiolillo, {Dominick J} and Bhatt, {Deepak L} and {LANCELOT-CAD Investigators}",

year = "2011",

month = may,

day = "3",

doi = "10.1161/CIRCULATIONAHA.110.001404",

language = "English",

volume = "123",

pages = "1854--63",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott, Williams and Wilkins",

number = "17",

}

Wiviott, SD, Flather, MD, O'Donoghue, ML, Goto, S, Fitzgerald, DJ, Cura, F, Aylward, P, Guetta, V, Dudek, D, Contant, CF, Angiolillo, DJ, Bhatt, DL & LANCELOT-CAD Investigators 2011, 'Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial', Circulation, vol. 123, no. 17, pp. 1854-63. https://doi.org/10.1161/CIRCULATIONAHA.110.001404

Randomized trial of atopaxar in the treatment of patients with coronary artery disease : the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial. / Wiviott, Stephen D; Flather, Marcus D; O'Donoghue, Michelle L et al.

In: Circulation, Vol. 123, No. 17, 03.05.2011, p. 1854-63.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Randomized trial of atopaxar in the treatment of patients with coronary artery disease

T2 - the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

AU - Wiviott, Stephen D

AU - Flather, Marcus D

AU - O'Donoghue, Michelle L

AU - Goto, Shinya

AU - Fitzgerald, Desmond J

AU - Cura, Fernando

AU - Aylward, Philip

AU - Guetta, Victor

AU - Dudek, Dariusz

AU - Contant, Charles F

AU - Angiolillo, Dominick J

AU - Bhatt, Deepak L

AU - LANCELOT-CAD Investigators

PY - 2011/5/3

Y1 - 2011/5/3

N2 - Thrombin is a key mediator of platelet activation. Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes with thrombin-mediated platelet effects. The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD.

AB - Thrombin is a key mediator of platelet activation. Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes with thrombin-mediated platelet effects. The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD.

KW - Aged

KW - Biological Markers

KW - Blood Platelets

KW - Coronary Artery Disease

KW - Dose-Response Relationship, Drug

KW - Female

KW - Hemorrhage

KW - Humans

KW - Imines

KW - Male

KW - Middle Aged

KW - Platelet Activation

KW - Platelet Aggregation Inhibitors

KW - Pyridines

KW - Receptors, Thrombin

U2 - 10.1161/CIRCULATIONAHA.110.001404

DO - 10.1161/CIRCULATIONAHA.110.001404

M3 - Article

C2 - 21502571

VL - 123

SP - 1854

EP - 1863

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 17

ER -